The binding of MET with its ligand (hepatocyte growth factor) activates downstream signaling pathways, including phosphoinositide 3-kinase (PI3K)/Akt, Ras-Rac/Rho, MAPK, and phospholipase C-γ [64], frequently activated in human cancers [68]. The gene discussed is RHO; the disease is cancer.